发布求助
文献互助 智能选刊 最新文献

Heart International最新文献

筛选
英文 中文
Mavacamten: A First-in-class Oral Modulator of Cardiac Myosin for the Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy. 马伐卡坦:治疗症状性肥厚性梗阻性心肌病的一流口服心肌蛋白调节剂。
IF 0.2
Heart International Pub Date : 2022-01-01 DOI: 10.17925/HI.2022.16.2.91
Klevin Roger L Reyes, Gizem Bilgili, Florian Rader
{"title":"Mavacamten: A First-in-class Oral Modulator of Cardiac Myosin for the Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy.","authors":"Klevin Roger L Reyes,&nbsp;Gizem Bilgili,&nbsp;Florian Rader","doi":"10.17925/HI.2022.16.2.91","DOIUrl":"https://doi.org/10.17925/HI.2022.16.2.91","url":null,"abstract":"<p><p>Hypertrophic cardiomyopathy is the most common monogenic cardiovascular disease that is caused by sarcomeric protein gene mutations. A hallmark of the most common form of the disease is outflow obstruction secondary to systolic narrowing of the left ventricular outflow tract from septal hypertrophy, mitral valve abnormalities and, most importantly, hyperdynamic contractility. Recent mechanistic studies have identified excessive myosin adenosine triphosphatase activation and actin-myosin cross-bridging as major underlying causes. These studies have led to the development of mavacamten, a first-in-class myosin adenosine triphosphatase inhibitor and the first specific therapy for hypertrophic obstructive cardiomyopathy. Preclinical and subsequent pivotal clinical studies have demonstrated the efficacy and safety of mavacamten. A remarkable improvement among treated patients in peak oxygen consumption, functional capacity, symptom relief and post-exercise left ventricular outflow tract gradient, along with dramatic reductions in heart failure biomarkers, suggests that this new medication will be transformative for the symptom management of hypertrophic obstructive cardiomyopathy. There is also hope and early evidence that mavacamten may delay or obviate the need for invasive septal reduction therapies. In this article, we review the current evidence for the efficacy and safety of mavacamten and highlight important considerations for its clinical use.</p>","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"16 2","pages":"91-98"},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872784/pdf/heart-int-16-91.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10716072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Side Branch is the Main Determinant Factor of Bifurcation Lesion Complexity: Critical Review with a Proposal Based on Single-centre Experience. 侧支是分叉病变复杂性的主要决定因素：基于单中心经验的批判性回顾与建议
IF 1.9
Heart International Pub Date : 2021-12-21 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.2.67
Imad Sheiban, Filippo Figini, Valeria Gasparetto, Fabrizio D'Ascenzo, Claudio Moretti, Filippo Leonardo
{"title":"Side Branch is the Main Determinant Factor of Bifurcation Lesion Complexity: Critical Review with a Proposal Based on Single-centre Experience.","authors":"Imad Sheiban, Filippo Figini, Valeria Gasparetto, Fabrizio D'Ascenzo, Claudio Moretti, Filippo Leonardo","doi":"10.17925/HI.2021.15.2.67","DOIUrl":"10.17925/HI.2021.15.2.67","url":null,"abstract":"<p><p>Although bifurcation stenting can be often managed with a simple provisional approach, in some settings, more complex techniques are appropriate. Based on our clinical experience and on data from literature, we propose a simple algorithm that may assist in selecting cases for elective double stenting. We found that, when the side branch is of adequate dimensions and affected by significant disease (longer than 10 mm and/or with presence of ostial calcifications), double stenting is associated with a lower incidence of adverse events, compared with provisional stenting.</p>","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"15 2","pages":"67-72"},"PeriodicalIF":1.9,"publicationDate":"2021-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524656/pdf/heart-int-15-67.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40654080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Narrative Review of Ultrathin-strut Drug-eluting Stents: The Thinner the Better? 超薄支架药物洗脱支架的述评:越薄越好?
IF 0.2
Heart International Pub Date : 2021-12-21 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.2.84
Maik J Grundeken, Marcel Am Beijk
{"title":"A Narrative Review of Ultrathin-strut Drug-eluting Stents: The Thinner the Better?","authors":"Maik J Grundeken,&nbsp;Marcel Am Beijk","doi":"10.17925/HI.2021.15.2.84","DOIUrl":"https://doi.org/10.17925/HI.2021.15.2.84","url":null,"abstract":"<p><p>Second-generation drug-eluting stents (DES) are considered standard of care for revascularization of patients undergoing percutaneous coronary intervention. Besides the polymer and antiproliferative drug used, the metallic backbone of DES is an attractive target for further development. Ultrathin-strut DES (≤70 μm strut thickness) are more flexible, have an improved trackability and crossability compared to conventional second-generation DES. Importantly, ultrathin-strut DES reduce the risk of in-stent restenosis, thereby decreasing the risk of angiographic and clinical restenosis. In this narrative review, we will discuss the clinical outcomes of the commercially available ultrathin-strut DES.</p>","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"15 2","pages":"84-93"},"PeriodicalIF":0.2,"publicationDate":"2021-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524587/pdf/heart-int-15-84.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40654082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Latest Advances in Transcatheter Mitral Valve Replacement. 经导管二尖瓣置换术的最新进展。
IF 0.2
Heart International Pub Date : 2021-12-20 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.2.79
Tomoya T Hinohara, Michael J Reardon, Sachin S Goel
{"title":"Latest Advances in Transcatheter Mitral Valve Replacement.","authors":"Tomoya T Hinohara,&nbsp;Michael J Reardon,&nbsp;Sachin S Goel","doi":"10.17925/HI.2021.15.2.79","DOIUrl":"https://doi.org/10.17925/HI.2021.15.2.79","url":null,"abstract":"<p><p>Mitral regurgitation (MR) is the most prevalent valvular heart disease globally. Mitral valve surgery is the gold-standard treatment for MR. However, a significant portion of patients with mitral valve disease are at high or prohibitive surgical risk. Transcatheter mitral valve replacement (TMVR) has emerged as a potential treatment option for this vulnerable population. Numerous TMVR devices are currently being investigated, with early data demonstrating feasibility and efficacy of TMVR. In this article, we explore the unique challenges of designing a TMVR system and describe the TMVR systems under clinical evaluation.</p>","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"15 2","pages":"79-83"},"PeriodicalIF":0.2,"publicationDate":"2021-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524844/pdf/heart-int-15-79.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40654079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Endoleak after Endovascular Abdominal Aortic Aneurysm Repair Treated by Bilateral Transradial Access: Case Report. 双侧经桡动脉通路治疗腹主动脉瘤腔内修复术后腔内渗漏1例。
IF 0.2
Heart International Pub Date : 2021-12-20 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.2.106
Gustavo A Samaja, Heber Tejerina Segovia, José M Escalante, Corina Biagioni, Silvana Onorato Grats
{"title":"Endoleak after Endovascular Abdominal Aortic Aneurysm Repair Treated by Bilateral Transradial Access: Case Report.","authors":"Gustavo A Samaja,&nbsp;Heber Tejerina Segovia,&nbsp;José M Escalante,&nbsp;Corina Biagioni,&nbsp;Silvana Onorato Grats","doi":"10.17925/HI.2021.15.2.106","DOIUrl":"https://doi.org/10.17925/HI.2021.15.2.106","url":null,"abstract":"<p><p>The treatment of endovascular leaks after endovascular abdominal aortic repair can be challenging, particularly in patients with a lack of vascular access. We describe the case of a critically ill elderly patient with an endoleak resulting from structural failure of an endograft years after endovascular abdominal aortic repair. The patient was treated with an aorto-uni-iliac endoprosthesis, but a few days later a new endoleak appeared and femoral or axillar access was not feasible. We successfully treated the endoleak using a novel technique via bilateral transradial access involving simultaneous insufflation of two peripheral low-profile balloons to achieve a diameter capable of improving the apposition of the stent graft. In selected cases, bilateral radial access allows procedures to be performed that would otherwise be impossible due to the inherent limitation in sheath size that can be used in the radial artery.</p>","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"15 2","pages":"106-111"},"PeriodicalIF":0.2,"publicationDate":"2021-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524746/pdf/heart-int-15-106.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40654081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Coronary Revascularization and Out-of-hospital Cardiac Arrest: Past, Present and Future. 冠状动脉血管重建与院外心脏骤停：过去、现在和未来。
IF 0.2
Heart International Pub Date : 2021-12-20 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.2.94
Matthew E Li Kam Wa, Kalpa De Silva, Nilesh Pareek, Divaka Perera
{"title":"Coronary Revascularization and Out-of-hospital Cardiac Arrest: Past, Present and Future.","authors":"Matthew E Li Kam Wa, Kalpa De Silva, Nilesh Pareek, Divaka Perera","doi":"10.17925/HI.2021.15.2.94","DOIUrl":"10.17925/HI.2021.15.2.94","url":null,"abstract":"<p><p>Cardiologists and the cardiac catheter laboratory have key roles to play in the management of patients after out-of-hospital cardiac arrest (OHCA). Although immediate catheter laboratory activation is the standard of care in cardiogenic shock and ST elevation myocardial infarction, the majority of patients will present without these features and with an uncertain diagnosis. Even in the latter, early assessment and invasive management may be beneficial, but this is counterbalanced by significant resource utilization, potential to cause harm and the possibility that any diagnostic or therapeutic gains are offset by a poor neurological outcome. Past consensus on the management of the OHCA patient without ST elevation or cardiogenic shock is being challenged by emerging results from new trials in this field. Further randomized trials are ongoing, and are expected to deliver robust data from over 4,000 patients, allowing us to further refine the optimal management strategy in this challenging cohort. This article describes the benefits and pitfalls of a strategy of immediate coronary angiography in these patients, examines the recently published COACT and TOMAHAWK trials in detail, and describes a framework with which to approach the patient after resuscitated OHCA, based on the available evidence to date.</p>","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"15 2","pages":"94-102"},"PeriodicalIF":0.2,"publicationDate":"2021-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524604/pdf/heart-int-15-94.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40655532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
XIENCE Implantation Followed By Short Dual Antiplatelet Therapy: 'The New Normal'? XIENCE植入后短期双重抗血小板治疗:“新常态”?
IF 0.2
Heart International Pub Date : 2021-12-10 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.2.65
Niels Mr van der Sangen, Wouter J Kikkert, José Ps Henriques, Bimmer Epm Claessen
{"title":"XIENCE Implantation Followed By Short Dual Antiplatelet Therapy: 'The New Normal'?","authors":"Niels Mr van der Sangen,&nbsp;Wouter J Kikkert,&nbsp;José Ps Henriques,&nbsp;Bimmer Epm Claessen","doi":"10.17925/HI.2021.15.2.65","DOIUrl":"https://doi.org/10.17925/HI.2021.15.2.65","url":null,"abstract":"<p><p>The XIENCE family of everolimus-eluting stents ranks among the most used and most widely studied drug-eluting stents worldwide. In patients at high bleeding risk undergoing non-complex percutaneous coronary intervention with these stents, a shortened dual antiplatelet therapy (DAPT) regimen of 1-3 months appears to be associated with a reduced rate of major bleeding, a similar rate of ischaemic events and a very low incidence of stent thrombosis after DAPT discontinuation compared with DAPT up to 12 months.</p>","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"15 2","pages":"65-66"},"PeriodicalIF":0.2,"publicationDate":"2021-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524721/pdf/heart-int-15-65.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40654078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
An Update on Drug-eluting Technology in Peripheral Arteries to Treat Peripheral Arterial Disease. 外周动脉药物洗脱技术治疗外周动脉疾病的研究进展
IF 0.2
Heart International Pub Date : 2021-12-10 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.2.73
Leonardo Marques, Silke Hopf-Jensen, Michael Preiss, Stefan Mueller-Huelsbeck
{"title":"An Update on Drug-eluting Technology in Peripheral Arteries to Treat Peripheral Arterial Disease.","authors":"Leonardo Marques,&nbsp;Silke Hopf-Jensen,&nbsp;Michael Preiss,&nbsp;Stefan Mueller-Huelsbeck","doi":"10.17925/HI.2021.15.2.73","DOIUrl":"https://doi.org/10.17925/HI.2021.15.2.73","url":null,"abstract":"<p><p>For the treatment of peripheral arterial disease, drug-eluting technology is a widely accepted therapeutic option, with significant reduction in intimal hyperplasia and, consequently, use of target lesion revascularization. Nevertheless, the reputation of such devices was damaged after a meta-analysis, published in December 2018, showed increased mortality in patients receiving paclitaxel-eluting devices. Although subsequent studies have failed to establish such correlation, the use of paclitaxel-eluting devices remains heavily restricted. As such, other options and drugs have been developed, for instance sirolimus. In this article we present the available data on drug-eluting technology.</p>","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"15 2","pages":"73-78"},"PeriodicalIF":0.2,"publicationDate":"2021-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524588/pdf/heart-int-15-73.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40654077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
An Unusual Cause of Pacemaker Lead Displacement: 'Reverse Ratchet' Syndrome. 起搏器导线移位的一个特殊原因：“反向棘轮”综合征。
IF 0.2
Heart International Pub Date : 2021-11-16 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.2.103
Haytham Enab, Colin Cunnington, Amir Zaidi
{"title":"An Unusual Cause of Pacemaker Lead Displacement: 'Reverse Ratchet' Syndrome.","authors":"Haytham Enab,&nbsp;Colin Cunnington,&nbsp;Amir Zaidi","doi":"10.17925/HI.2021.15.2.103","DOIUrl":"https://doi.org/10.17925/HI.2021.15.2.103","url":null,"abstract":"<p><p>Lead displacement is a common complication of pacemaker device implantation, often resulting in prolonged hospital stays and increased costs. The frequency of long-term lead displacement ranges between 1.8% and 8.0%. In our case, the patient did not present any symptoms and the lead displacement was seen at a relatively late stage. During a routine pacemaker follow up, it was noted that the right ventricular (RV) threshold had increased and deteriorated over time. The pacemaker box had rotated anticlockwise and the RV lead had developed a loop that eventually led to its retraction from the RV implantation position into the pulmonary artery. The patient was asymptomatic; however, he underwent RV lead revision. Patient education, opening an appropriate pocket for the size of the generator, fixing the sleeves to an appropriate tightness and securing the battery with a strong suture all can be used to avoid lead displacement.</p>","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"15 2","pages":"103-105"},"PeriodicalIF":0.2,"publicationDate":"2021-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524719/pdf/heart-int-15-103.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40654083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The HEP-COVID Trial. HEP-COVID试验。
IF 0.2
Heart International Pub Date : 2021-10-21 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.2.62
Alex C Spyropoulos
{"title":"The HEP-COVID Trial.","authors":"Alex C Spyropoulos","doi":"10.17925/HI.2021.15.2.62","DOIUrl":"https://doi.org/10.17925/HI.2021.15.2.62","url":null,"abstract":"<p />","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"15 2","pages":"62-64"},"PeriodicalIF":0.2,"publicationDate":"2021-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524691/pdf/heart-int-15-62.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40666258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信